Adding Ofra-Vec to Chemo Does Not Improve PFS, OS in Platinum-Resistant Ovarian Cancer
Cancer Therapy Advisor,
Adding ofranergene obadenovec (ofra-vec) to chemotherapy does not improve outcomes in patients with platinum-resistant ovarian…
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Overview of attention for article published in Journal of Clinical Oncology, October 2023
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (89th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 22 Mendeley